Track market-moving stories before they get noisy

MSCI (MSCI - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for MSCI basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For MSCI, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for MSCIFor the fiscal year ending December 2026, this maker of software tools to help portfolio managers make investment decisions is expected to earn $19.62 per share, which is unchanged compared with the year-ago reported number.

Analysts have been steadily raising their estimates for MSCI. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.9%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of MSCI to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / June 16, 2026 / MSC Industrial Supply Co. (NYSE:MSM) ("MSC," "MSC Industrial," the "Company," "we," "us," or "our"), a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services, today announced that its Board of Directors has declared a cash dividend of $0.87 per share. The $0.87 dividend is payable on July 22, 2026 to shareholders of record at the close of business on July 8, 2026.

# # #

About MSC Industrial Supply Co.

MSC Industrial Supply Co. (NYSE: MSM) is a leading North American distributor of a broad range of metalworking, maintenance, repair and operations (MRO), and production fastener and hardware products and services. With approximately 2.5 million products, industry‑leading inventory management and supply chain solutions, and more than 80 years of experience, we help customers improve productivity, profitability, and operational performance.

Our team of over 7,000 associates partners closely with customers across industries to keep their operations running efficiently today while enabling them with insights and comprehensive solutions to continually rethink, retool, and optimize for a more productive tomorrow.

For more information on MSC Industrial, please visit mscdirect.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words "will," "may," "believes," "anticipates," "thinks," "expects," "estimates," "plans," "intends" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management's assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology ("IT") systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

SOURCE: MSC Industrial Direct Co.

LOS ANGELES, June 15, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Calix, Inc. (“Calix” or “the Company”) (NYSE: CALX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 27, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Calix’s Q1 margins benefited from the advanced purchasing of memory components. The Company’s supply of these memory components was rapidly decreasing due to these advanced orders. The Company’s margin faced negative pressure based on the purchase of memory at increasing market prices. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Calix, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

-

SC builds on a more than 20-year partnership with Calix and proven success on the Calix platform—delivering differentiated subscriber experiences across residential, business, and community markets, including outdoor Wi‑Fi—to now securely accelerate with agentic capabilities on Calix One

SAN JOSE, Calif.--(BUSINESS WIRE)--Calix, Inc. (NYSE: CALX) today announced that SC (formerly SCTelcom) is expanding their more than 20-year partnership with Calix—building on a proven model of delivering differentiated experiences across residential, business, and community markets—to deploy Calix Agent Workforce™ Cloud on the AI-native Calix One™ platform and accelerate growth.

“What excites me most is the direction we’re heading together. The Calix vision of an ‘experience of one’ aligns with how we believe service should feel—personal, responsive, and rooted in real relationships,” said Carla Shearer, CEO/General Manager at SC.

Share SC, which has served rural Kansas and Oklahoma communities since 1953, has built their business on delivering differentiated subscriber experiences across markets with SmartLife™ managed services. These span secure SmartHome™ experiences that include outdoor Wi-Fi, small business growth with SmartBiz™, and community-wide connectivity with SmartTown®. SC has already seen robust results with the Calix platform: a full return on their cloud investment in four months, zero call center churn with 100 percent support staff retention, a Net Promoter Score℠ (NPS®) of 90—up from 79 in just two years, and a 3 percent increase in average revenue per user in six months—all while scaling performance without adding operational overhead.

With agentic-driven workflows on the Calix One platform, SC can accelerate growth through more personalized subscriber engagement, improved segmentation and targeting, and consistent experiences at scale—helping reduce operating expenses (OPEX) to fund continued expansion. To support this transformation, SC leadership is working with Calix Success™ and using the Calix AI Leadership Playbook to guide organization-wide enablement and accelerate adoption of agentic capabilities.

Carla Shearer, chief executive officer and general manager at SC, said: “Over our 20-year partnership with Calix, we’ve built something that truly works—for our subscribers and for our business. We’re delivering a strong experience, reflected in a 90 NPS and no staff turnover, while keeping our operation simple and sustainable.

“What excites me most is the direction we’re heading together. The Calix vision of an ‘experience of one’ aligns with how we believe service should feel—personal, responsive, and rooted in real relationships. At the same time, it helps us run more efficiently and manage OPEX in a way that allows us to reinvest right back into the communities we serve.

“As we evolve how we work—bringing our teams together with agentic capabilities through Calix One—we’re able to spend less time on friction and more time where it matters most: strengthening subscriber relationships and delivering faster, more personalized engagement. That’s how we continue to grow and stay relevant in the AI era.”

Michael Weening, president and chief executive officer at Calix, said: “Since November 2023, we have deliberately invested to evolve our platform so AI works natively within provider workflows—securely and at scale. Over decades of partnership with Calix, SC has built a business that delivers differentiated experiences and drives loyalty and growth. We are proud to support their continued success as they enable human-AI collaboration within their teams to drive efficiency, strengthen subscriber relationships, and allow them to compete and win in any market.”

Learn how Calix One is helping service providers transform their business by leveraging the AI Leadership Playbook, exploring the award-winning “AI Academy” in Calix University, and attending Calix Customer Success webinars.

About Calix

Calix, Inc. (NYSE: CALX) is an AI platform company that enables service providers to transform their operations and accelerate delivery of differentiated experiences—so they can compete and win in the markets and communities they serve.

Through the AI-native Calix One platform, service providers can securely and privately activate agentic-AI alongside their human teams to acquire new subscribers, grow existing subscriber revenue, and build loyalty across residential, business, municipal, and MDU markets. More than 1,200 customers of all sizes leverage the Calix One platform, which has evolved over 15 years at an investment of more than $2 billion.

Calix innovation cycles are underpinned by a strong financial balance sheet and a people‑first culture that routinely earns broad industry recognition—winning 81 culture and innovation awards since 2025 alone, as well as Fortune’s 100 Best Companies to Work For® in 2026.

This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix’s business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix’s results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at www.sec.gov.

Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix’s trademarks can be found at https://www.calix.com/legal/trademarks.html. Third-party trademarks mentioned are the property of their respective owners.

Net Promoter®, NPS®, NPS Prism®, and the NPS-related emoticons are registered trademarks of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld. Net Promoter Score℠ and Net Promoter System℠ are service marks of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld.

More News From Calix, Inc.

Back to Newsroom

New York, New York--(Newsfile Corp. - June 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301737

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways CRGY's 2026 outlook gains visibility from its oil-weighted portfolio and Permian integration progress.CRGY captured about $120M of Vital Energy synergies by Q1 2026, topping its initial target.CRGY expects roughly $1B of 2026 levered free cash flow and about $2B of liquidity. Crescent Energy Company (CRGY - Free Report) is drawing attention as its oil-weighted portfolio, tighter execution and integration progress improve the visibility of its 2026 cash flow profile.

The setup is not without risk, but the company’s Permian progress, minerals exposure and capital-return flexibility give investors a clearer framework for evaluating the stock.

Crescent’s Oil Mix Supports Margins

Crescent’s production base is tilted toward oil and liquids, which generally carry better economics than dry gas. That mix helps support margins when commodity markets are uneven.

The company also uses marketing and hedging to reduce exposure to regional price swings, particularly in natural gas. That does not eliminate commodity risk, but it can make cash flows more predictable across cycles.

CRGY’s Permian Deal Is Paying Off

The Vital Energy integration is the central near-term catalyst for CRGY. By the first quarter of 2026, Crescent had already captured about $120 million of synergies, above its initial target.

Operational gains are also showing up in the development plan. Crescent added roughly 100,000 lateral feet to its 2026 program, accelerated production by about 100 producing days and reduced well costs by more than $500,000 per well versus the prior operator.

Image Source: Crescent Energy Company

Crescent’s Cash Flow Case for 2026

The financial case rests on free cash flow. Management expects roughly $1 billion of 2026 levered free cash flow at current commodity prices, helped by a lower-capital-intensity asset base.

That matters because liquidity and maturity timing shape capital flexibility. Crescent has about $2 billion of liquidity and no significant near-term debt maturities, giving it room to fund development, pay dividends, repurchase shares and pursue selective deals.

Image Source: Crescent Energy Company

Diamondback Energy (FANG - Free Report) offers a useful comparison because it is a Permian-focused oil and gas producer. For investors watching Crescent’s Permian integration, FANG remains a relevant benchmark for basin execution and capital discipline.

CRGY’s Minerals Unit Adds Stability

Crescent’s Minerals & Royalties business adds another layer to the cash flow story. The segment is expected to generate about $200 million of EBITDA in 2026.

The appeal is its low-capital structure. With minimal capital requirements and diversified exposure across key U.S. basins, the business can provide steadier cash generation alongside Crescent’s working-interest portfolio.

EOG Resources (EOG - Free Report) is another relevant name in the U.S. exploration and production space. Its scale and onshore resource base make it a useful peer when investors compare asset quality, execution and commodity exposure.

Crescent’s Key Risks Still Matter

Commodity prices remain the largest swing factor. Weaker oil, natural gas or NGL prices could pressure cash flow, slow drilling activity or limit shareholder returns.

Debt is another constraint. Crescent carries $5.2 billion of long-term debt, and debt-to-capitalization is above 50%, leaving less margin for error if prices weaken or acquisition benefits take longer to materialize.

CRGY’s Ratings Reinforce the Bull Case

The bottom line is that Crescent’s 2026 outlook looks more constructive as Permian synergies build, minerals cash flow expands and free cash flow supports capital flexibility. The stock still requires tolerance for commodity and balance-sheet risk.

CRGY currently carries a Zacks Rank #1 (Strong Buy). It also has a VGM Score of A, Value Score of A, Growth Score of D and Momentum Score of B.

You can see the complete list of today’s Zacks #1 Rank stocks here.

That combination points to a favorable near-term setup for investors looking for value and momentum exposure. Growth is not the main appeal, but the Rank and Style Scores support a constructive view for investors comfortable with energy-sector cyclicality.

Key Takeaways Crescent highlights the shift toward durable free cash flow over aggressive production growth.CRGY's oil-weighted assets span Eagle Ford, Permian and Uinta, with 96% acreage held by production.Crescent captured about $120M in Vital Energy synergies and expects $200M EBITDA from minerals. Crescent Energy Company (CRGY - Free Report) sits at the center of a timely energy-equity theme: investors are giving more attention to producers that can generate durable free cash flow without chasing production growth at any cost.

The company’s setup combines oil-weighted assets, capital discipline, acquisition integration and royalty exposure, making it a useful case study for a cash-flow-first market.

Crescent Fits the Cash Flow First Trend

Crescent’s portfolio is designed around steady cash generation rather than aggressive volume expansion. Its long-life asset base spans the Eagle Ford, Permian and Uinta, giving the company multiple reinvestment options across established U.S. basins.

Image Source: Crescent Energy Company

A key part of that flexibility is lease control. About 96% of Crescent’s acreage was held by production at year-end 2025, reducing the pressure to drill simply to preserve acreage. That supports a more disciplined capital plan.

CRGY Shows Why Oil Weight Matters

Crescent’s asset mix also fits the market’s preference for liquids-rich production. Liquids represented about 61% of proved reserves at year-end 2025, while first-quarter 2026 production was 41% oil and 64% liquids.

That oil and liquids exposure can support stronger margins than a gas-heavy profile, while Crescent’s hedging and marketing strategy helps moderate commodity swings. Diamondback Energy (FANG - Free Report) , a Permian-focused oil and natural gas producer, and Matador Resources Company (MTDR - Free Report) , an independent energy company active in oil and gas exploration and production, give investors broader context for why liquids-rich U.S. shale exposure remains an important comparison point.

Crescent Benefits from Integration Expertise

Crescent also reflects the sector’s consolidation-and-optimization trend. The company’s strategy depends on acquiring cash-flow-oriented assets, improving operations and making returns-focused reinvestment decisions.

The Vital Energy integration has strengthened that argument. Crescent had captured roughly $120 million in synergies by the first quarter of 2026, exceeding its original target, while also reducing well costs by more than $500,000 per well versus the prior operator.

CRGY’s Royalty Exposure Adds a Trend Angle

The Minerals & Royalties business adds another quality-of-earnings angle. Royalty interests generate revenue without requiring Crescent to fund day-to-day drilling and operating costs on those wells.

That makes the business a high-margin, low-capital cash flow stream. Management expects about $200 million of EBITDA from the segment in 2026, and leverage in the minerals unit is expected to decline toward 1.5X or lower by the end of 2026.

Image Source: Crescent Energy Company

Crescent Also Reflects the Limits of the Trend

Even a disciplined cash-flow model remains tied to old energy-sector risks. Crescent’s earnings and cash flow are still sensitive to oil, natural gas and NGL prices.

Leverage and deal execution also matter. A weaker commodity backdrop, slower acquisition integration or lower-than-expected returns could pressure free cash flow and limit flexibility for dividends, buybacks, debt reduction or additional transactions.

CRGY’s Ratings Signal a Trend in Favor

The bottom line is that Crescent offers exposure to several investor-friendly energy themes: oil-rich production, lower capital intensity, free cash flow, integration upside and royalty-driven margins. Those strengths do not remove commodity risk, but they help explain why CRGY stands out in the current setup.

The stock currently carries a Zacks Rank #1 (Strong Buy). It also has a VGM Score of A, Value Score of A and Momentum Score of B. Since Style Scores are designed to complement the Zacks Rank, those grades suggest CRGY has favorable value and overall style characteristics, with momentum also supportive, though not without the sector risks that come with energy exposure.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Fluence Energy, Inc. is evolving into a pure play on critical power infrastructure for AI, renewables, and grid reliability. FLNC is a High-Risk Buy, supported by record backlog, hyperscaler agreements, and third-party validation of 99%+ fleet availability. Q2 results show 7.7% revenue growth, reaffirmed FY2026 guidance ($3.2B–$3.6B revenue, $40M–$60M adjusted EBITDA), and $180M targeted recurring revenue.

Key Takeaways Baxter is advancing a turnaround strategy focused on operational discipline and balance sheet repair.BAX saw strong Q1 growth in Advanced Surgery and Healthcare Technology despite broader weakness.Baxter faces pressure from Novum pump regulatory issues, margin compression and flat 2026 sales outlook. Baxter International (BAX - Free Report) entered 2026 focused on executing a broad turnaround strategy aimed at restoring growth, improving cash flow and strengthening operational discipline. While innovation initiatives, solid demand in select businesses and improving balance-sheet trends support its long-term outlook, regulatory challenges, margin pressure and continued weakness in certain core segments remain significant near-term headwinds.

Shares of this Zacks Rank #3 (Hold) company have gained 8.9% so far this year against the industry's 23.2% decline. The S&P 500 Index has jumped 8.6% during the same time frame.

BAX, with a market capitalization of $10.1 billion, is a global medical technology company providing items, such as infusion pumps and intravenous solutions. The company has an earnings yield of 9.2% compared with the industry's 3.3%. It anticipates earnings to improve 3.2% over the next five years.

Image Source: Zacks Investment Research

Positive Factors Driving ProspectsTurnaround Strategy Leading to Operational Progress: Baxter’s new management team is focused on stabilizing the business through its multi-pronged turnaround strategy centered on operational discipline, balance sheet repair and continuous improvement. The newly implemented Baxter Growth and Performance System (“GPS”) has already driven more than several improvement initiatives across the organization, helping improve execution, service reliability and working capital efficiency.

While the turnaround remains in its early stages, the framework introduces greater accountability by decentralizing P&L ownership and streamlining decision-making. This operational transformation should gradually restore consistency in revenue growth, improve margins and rebuild investor confidence.

Advanced Surgery and Healthcare Technology Remain Resilient: Despite broader operational challenges, Baxter continues to benefit from strong demand in several higher-growth businesses. Advanced Surgery revenues grew 10% in the first quarter of 2026, supported by steady procedure volumes and continued demand for hemostats and sealants across global markets.

In Healthcare Systems & Technologies, management highlighted strong momentum in Patient Support Systems and a healthy U.S. capital equipment order book, suggesting that hospital capital spending remains resilient despite broader macroeconomic uncertainty. However, continued execution will be critical to sustaining this momentum and offsetting ongoing challenges in other areas of the business.

These businesses represent strategically attractive segments with better growth profiles than legacy infusion-related products. This provides Baxter with an important growth cushion while management works through operational and regulatory challenges elsewhere in the portfolio.

Innovation Pipeline and AI Integration to Support Growth: Baxter is increasingly positioning innovation as a future growth catalyst, with management highlighting multiple recent product launches, including Dynamo smart hospital stretcher, Connex 360 connected-care platform, IV Verified automated medication labeling system and XR spine surgical table.

BAX is also aggressively integrating AI into both product development and internal operational workflows. Management emphasized that AI is already being deployed across connected-care infrastructure, manufacturing systems and quality workflows to improve clinical decision-making and operational efficiency. 

Baxter’s growing emphasis on incremental innovation and AI-driven healthcare solutions could gradually improve its competitive positioning and likely lead to stronger organic growth drivers.

Key ChallengesCore Business Performance Remains Weak: Baxter’s underlying operating performance remains weak. First-quarter revenues increased 3%, reportedly, but organic sales declined 1%, while adjusted EPS fell sharply 35% year over year to 36 cents. Multiple core businesses remain under pressure, including Medical Products & Therapy, Healthcare Systems Technology and Pharmaceuticals.

The company’s guidance for approximately flat organic sales growth for full-year 2026 indicates management does not expect meaningful near-term acceleration. While executives are emphasizing second-half improvement, current performance suggests Baxter is still operating well below its earnings potential.

Novum Infusion Pump Regulatory Problems Continues: The largest company-specific overhang remains Baxter’s ongoing Novum LVP infusion pump regulatory issue, which continues to prevent shipment and installation activity.

Management confirmed that the shipment hold is fully reflected in its full-year guidance. However, the company acknowledged that customer returns or product exchanges could still occur, creating an additional layer of uncertainty around future financial performance.

Although customer returns were immaterial during the first quarter, management repeatedly emphasized it remains prudent to maintain this risk assumption throughout 2026. The infusion pump portfolio accounts for less than 2% of total revenues, but the broader concern extends beyond lost pump sales into associated high-margin consumables, customer retention and reputational damage within hospital infusion systems.

Margin Compression Remains Severe: Baxter’s profitability deteriorated significantly during the quarter as multiple external and operational pressures simultaneously hit margins. Adjusted gross margin declined 500 basis points to 36.8%, while operating margin fell 390 basis points to 11%.

Management cited approximately $50 million of cost timing headwinds, higher tariff-related costs, elevated manufacturing expenses and lower production absorption. The company continues to estimate a full-year tariff-related headwind of approximately $80 million. In addition, it remains exposed to inflationary pressures from higher oil prices, freight expenses, semiconductor supply constraints and rising raw-material costs, all of which could weigh on profitability if they persist.

Although management expects roughly 500 basis points of second-half margin recovery, much of the pressure stems from external factors outside Baxter’s control. Sustained cost inflation could materially delay the company’s earnings recovery timeline.

Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $11.36 billion, indicating a 1% improvement from the previous year’s level.

The consensus mark for adjusted earnings per share (EPS) is pinned at $1.92, indicating a 15.4% decrease from the year-ago reported number. The consensus estimate for adjusted EPS has improved 1 cent in the past 60 days.

Stocks to ConsiderSome better-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , West Pharmaceutical Services (WST - Free Report) and Cardinal Health (CAH - Free Report) .

Align Technology, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 7.80%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ALGN’s shares have gained 9.2% against the industry’s 4.2% decline so far this year.

West Pharmaceutical, currently carrying a Zacks Rank of 1, has an estimated long-term growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 19.37%.

West Pharmaceutical’s shares have gained 20.2% against the industry’s 4.2% decline year to date.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

CAH’s shares have gained 5.2% against the industry’s 4.2% decline so far this year.

, /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today announced that monthly fund composition and performance data for Federated Hermes Premier Municipal Income Fund (NYSE: FMN) as of May 31, 2026, is now available in the Products section of FederatedHermes.com/us. To order hard copies of this data or to be placed on a mailing list, call 800-245-0242 x5587538, email [email protected] or write to Federated Hermes, 1001 Liberty Avenue, Floor 23, Pittsburgh, PA 15222.

Federated Hermes, Inc. (NYSE: FHI) is a global leader in active, responsible investment management, with $907.1 billion in assets under management, as of March 31, 2026. We deliver investment solutions that help investors target a broad range of outcomes and provide equity, fixed-income, alternative/private markets, multi-asset and liquidity management strategies to more than 11,000 institutions and intermediaries worldwide. Our clients include corporations, government entities, insurance companies, foundations and endowments, banks and broker/dealers. Headquartered in Pittsburgh, Federated Hermes has more than 2,000 employees in London, New York, Boston and offices worldwide. For more information, visit FederatedHermes.com/us.

###

SOURCE Federated Hermes, Inc.

LOS ANGELES, June 15, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FS KKR Capital Corp. (“FSK” or “the Company”) (NYSE: FSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 3, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. FSK misled investors about the effectiveness of its portfolio restructuring activities. The Company overvalued its portfolio and overstated its portfolio valuation process. The Company overstated the strength of its quarterly dividend program. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about FSK, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

LOS ANGELES, June 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises FS KKR Capital Corp., (“FS KKR” or the "Company") (NYSE: FSK) investors of a class action on behalf of investors that bought securities between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”). FS KKR investors have until July 3, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/fs-kkr-capital-corp. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The FS KKR class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) FS KKR overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (ii) FS KKR overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR’s portfolio valuation process; and (iii) FS KKR overstated the durability of its quarterly distribution strategy.

The FS KKR class action lawsuit further alleges that on August 6, 2025, FS KKR reported second quarter 2025 earnings, revealing that FS KKR’s net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million. Moreover, FS KKR allegedly reported a loss per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter. Further, investments on non-accrual status allegedly rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter. On this news, the price of FS KKR stock fell more than 8%, according to the complaint.

Then, on February 25, 2026, FS KKR announced fourth quarter and full year 2025 earnings, allegedly revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from the prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million. Moreover, FS KKR allegedly reported a loss per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter. Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter.  FS KKR also allegedly “acknowledge[d] specific challenges” with additional companies and cut its dividend to $0.48 per share (previously $0.70). On the accompanying earnings call, FS KKR’s Chief Investment Officer, was allegedly forced to acknowledge that its “recent underperformance reflects challenges in certain legacy investments” in addition to those previously discussed, including Medallia and Cubic Corp. Further, challenges ran much deeper, as FS KKR revealed issues with the identified companies only accounted for “50% of net realized and unrealized losses.” On this news, the price of FS KKR stock fell more than 15%, according to the FS KKR class action lawsuit.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

LOS ANGELES, June 16, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 6, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FS KKR Capital Corp. (“FS KKR Capital” or the “Company”) (NYSE: FSK) securities between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR FS KKR CAPITAL INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On August 6, 2025, after the market closed, the Company reported second quarter 2025 earnings, revealing that the Company’s net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million. Moreover, the Company reported earnings (loss) per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter. Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.

However, the Company maintained that its “operating results and corresponding net asset value” were merely “impacted by company specific issues affecting four portfolio companies, each of which have been discussed on prior earnings calls.”

On this news, share prices fell $1.66 or 8.20% to close at $18.58 per share on August 7, 2025, on unusually heavy trading volume.

Then, on February 25, 2026, after the market closed, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million. Moreover, the Company reported earnings (loss) per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter. Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter. The Company also “acknowledge[d] specific challenges” with additional companies and cut its dividend to $0.48 per share (previously $0.70).

In the accompanying earnings call, the Company’s Chief Investment Officer was forced to acknowledge that its “recent underperformance reflects challenges in certain legacy investments” in addition to those previously discussed. Further, challenges ran much deeper, as the Company revealed issues with the identified companies only accounted for “50% of net realized and unrealized losses.”

On this news, the Company’s stock price fell $2.03 or 15.24%, to close at $11.29 per share on February 26, 2026, on unusually heavy trading volume.

What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired FS KKR securities during the Class Period, you may move the Court no later than July 6, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against FS KKR Capital Corp. (“FSK KRR” or the “Company”) (NYSE: FSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether FSK KRR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have July 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired FSK KRR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action] 

On August 6, 2025, the Company reported second quarter 2025 earnings, revealing that the Company’s net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million.  Moreover, the Company report earnings (loss) per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter.  Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.  

On this news, FS KKR’s stock price fell $1.66 per share, or 8.2%, to close at $18.58 per share on August 7, 2025. 

Then, on February 25, 2026, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million.  Moreover, the Company reported earnings (loss) per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter.  Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter.  The Company also “acknowledge[d] specific challenges” with additional companies and cut its dividend to $0.48 per share (previously $0.70). 

On this news, FS KKR’s stock price fell $2.03 per share, or 15.24%, to close at $11.29 per share on February 26, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: 
Danielle Peyton 
Pomerantz LLP 
[email protected] 
646-581-9980 ext. 7980 

, /PRNewswire/ -- Fulton Financial Corporation ("Fulton") (Nasdaq: FULT) today announced that its Board of Directors (the "Board") declared a quarterly cash dividend of nineteen cents per share on its common stock, payable on July 15, 2026, to shareholders of record as of July 1, 2026.

In addition, Fulton announced that the Board declared a quarterly dividend of $12.81 per share (equivalent to $0.32025 per depositary share) on its Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on July 15, 2026, to shareholders of record as of June 30, 2026, for the period from and including April 15, 2026, to but excluding, July 15, 2026.

Fulton, a more than $34 billion Lancaster, Pennsylvania-based financial holding company, has more than 3,400 employees and operates more than 200 financial centers in Pennsylvania, New Jersey, Maryland, Delaware and Virginia through Fulton Bank, N.A.

Additional information on Fulton can be found at investor.fultonbank.com.

Media:
Rachel Sharkey (717) 291-2831

Investors:
Patrick Lafferty (717) 327-2556

SOURCE Fulton Financial Corporation

Key Takeaways Eaton will combine its Mobility Group with Dana to create a company valued at more than $10B.The deal sharpens Eaton's focus on higher-growth, higher-margin Electrical and Aerospace segments.Eaton will receive $1.1B in cash, while shareholders will own at least 50.1% of the company. Eaton Corporation (ETN - Free Report) has announced an agreement with Dana Incorporated to combine its Mobility Group with Dana through a Reverse Morris Trust (RMT) transaction. This will aid Eaton in its ongoing portfolio transformation and support its 2030 growth strategy. The transaction will create a combined company valued at more than $10 billion and further streamline Eaton’s business portfolio.

The move strengthens Eaton’s focus on its higher-growth, higher-margin Electrical and Aerospace segments. The company’s long-term strategy is centered on benefiting from major secular growth drivers, including electrification, digitalization, AI-powered data center expansion, infrastructure modernization, aerospace aftermarket demand and increased defense spending. Over the years, Eaton has steadily reduced its reliance on cyclical automotive markets and shifted toward intelligent power management and electrical solutions, resulting in stronger margins, improved recurring revenue visibility and enhanced cash flow generation.

The Dana transaction represents another milestone in Eaton’s portfolio optimization efforts. By combining its Mobility business with Dana, Eaton separates a mature automotive operation while retaining exposure to vehicle electrification opportunities through ownership and strategic participation in the new entity. Eaton’s Mobility Group is valued at approximately $5.1 billion, while the combined company is expected to generate about $11 billion in pro forma revenues and $1.7 billion in adjusted EBITDA in 2026.

Per the agreement, Eaton will receive approximately $1.1 billion in cash, and its shareholders will own at least 50.1% of the combined company. The deal is also expected to generate around $250 million in annual run-rate synergies. Expected to close in the first quarter of 2027, the transaction should immediately enhance Eaton’s organic growth profile and operating margins.

Overall, the deal reinforces Eaton’s transformation into a more focused electrification and power management leader positioned to capitalize on long-term infrastructure and energy transition trends.

What About ETN’s Peers?Emerson Electric (EMR - Free Report) continues to strengthen its market presence, customer base, and product portfolio through strategic acquisitions. These deals have enabled Emerson to enhance its automation capabilities and enter new markets. At the same time, Emerson is divesting non-core and underperforming businesses, which enables it to focus resources more effectively on its core operations.

Powel Industries (POWL - Free Report) is benefiting from global electrification and digitalization trends. Powel’s expanding presence across the electrical power value chain has driven strong bookings from utility and industrial markets. Additionally, Powel’s acquisition of Remsdaq strengthens its automation capabilities, enabling it to deliver more comprehensive electrical automation solutions to utility customers.

ETN Price PerformanceShares of Eaton have gained 28.7% year to date, outperforming the industry.

Image Source: Zacks Investment Research

ETN’s Expensive ValuationEaton’s shares are trading at a premium compared with its industry. The company’s forward 12-month price to earnings of 28.3X is higher than its industry’s 24.65X and above the median of 26.41X over the last three years.

Image Source: Zacks Investment Research

No Estimate Movement for ETNThe Zacks Consensus Estimate for ETN’s second-quarter and third-quarter 2026 EPS has witnessed no movement over the past seven days. The same holds true for 2026 and 2027 EPS estimates.
 

Image Source: Zacks Investment Research

POWAY, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- VyOS Networks today announced the availability of VyOS 1.5 LTS on Equinix Network Edge, bringing the latest long-term support release of the VyOS Universal Networking Platform to Equinix's global interconnection infrastructure. Enterprises, service providers, and infrastructure teams can now deploy VyOS 1.5 LTS as a virtual network function (VNF) on Equinix Network Edge, with access to Equinix Fabric and direct on-ramps to major cloud providers, including AWS, Microsoft Azure, and Google Cloud.

VyOS 1.5 LTS represents a significant step forward from the version originally introduced to Platform Equinix in 2023. The release introduces VPP (Vector Packet Processing), an accelerated dataplane that can deliver packet forwarding performance up to 15x faster than the standard Linux kernel dataplane, making it suited for high-throughput edge and hybrid cloud deployments where latency and throughput are critical. VPP can be deployed selectively on high-traffic interfaces while the kernel dataplane remains active, where full feature coverage is required, giving operators precise control over the performance and capability trade-off.

Beyond raw performance, VyOS 1.5 LTS brings a transactional CLI with commit and rollback, built-in configuration versioning, and automation-first integration designed to make network operations part of the delivery pipeline rather than a manual step outside of it. These capabilities are available consistently across all deployment targets, including bare metal, major hypervisors, public cloud, and Equinix Network Edge, under a single operational model and configuration interface.

On Equinix Network Edge, VyOS 1.5 LTS is available on month-to-month or committed term billing, priced by VNF size. Combined with VyOS's software subscription model, which carries no per-bandwidth, per-tunnel, or per-user fees, organizations can scale their edge network footprint without the licensing overhead that typically accompanies growth on traditional networking platforms.

"VyOS 1.5 LTS on Equinix Network Edge is the most capable version of VyOS we have brought to this platform," said Santiago Blanquet, Chief Revenue Officer at VyOS Networks. "Teams can now deploy high-performance, production-grade networking at the interconnection layer in minutes, with the same operational model they use everywhere else in their infrastructure. The combination of VPP acceleration, transactional configuration management, and a software cost model that does not penalize growth removes the barriers that used to make edge networking a slow and operationally fragmented exercise."

VyOS 1.5 LTS is available now on Equinix Network Edge across all supported metro locations. For more information, visit vyos.io or contact [email protected].

About VyOS Networks

VyOS Networks is the global leader in open-source networking, delivering secure, scalable, and automated solutions for organizations across bare metal, cloud, and edge environments. Built on Linux and trusted by enterprises, service providers, and integrators worldwide, VyOS provides an enterprise-grade platform that unifies advanced routing, firewall, and VPN capabilities with full control and zero vendor lock-in. Your network, your rules: adaptable, transparent, and future-proof by design, VyOS empowers you to operate with operational simplicity, high performance, continuous innovation, and cost-sustainable scalability.

For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Equinix (EQIX - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Finance sector should help us answer this question.

Equinix is a member of the Finance sector. This group includes 831 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Equinix is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for EQIX's full-year earnings has moved 2.3% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, EQIX has moved about 38.9% on a year-to-date basis. Meanwhile, the Finance sector has returned an average of 3.7% on a year-to-date basis. This means that Equinix is performing better than its sector in terms of year-to-date returns.

Another stock in the Finance sector, BNY (BNY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 22.8%.

In BNY's case, the consensus EPS estimate for the current year increased 4.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Equinix belongs to the REIT and Equity Trust - Retail industry, which includes 19 individual stocks and currently sits at #155 in the Zacks Industry Rank. Stocks in this group have gained about 21% so far this year, so EQIX is performing better this group in terms of year-to-date returns.

On the other hand, BNY belongs to the Banks - Major Regional industry. This 9-stock industry is currently ranked #41. The industry has moved +12.6% year to date.

Equinix and BNY could continue their solid performance, so investors interested in Finance stocks should continue to pay close attention to these stocks.

U.S. Confirmatory Registration Study expected to begin Summer 2026

Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life

Saudi partnership includes a 50%/50% net revenue share and supports potential patient access in one of the Middle East's largest oncology markets

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today highlighted its dual-track strategy to bring Multikine® (Leukocyte Interleukin, Injection)* to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia.

“Following extensive clinical development and close engagement with regulators, we are excited to begin our final Confirmatory Registration Study, aiming to extend lives and improve the quality of life for head and neck cancer patients,” said Geert Kersten

Share The Company plans to commence its Confirmatory Registration Study of Multikine this summer while simultaneously advancing regulatory and commercialization activities in Saudi Arabia through its strategic partnership with Saudi Amarox.

“Following extensive clinical development and close engagement with regulators, we are excited to begin our final Confirmatory Registration Study, aiming to extend lives and improve the quality of life for head and neck cancer patients,” said Geert Kersten, Chief Executive Officer of CEL-SCI. “We are also looking forward to participating in next week's signing ceremony at BIO with Amarox, our Saudi partner, as we advance a second pathway to bring Multikine to patients.”

U.S. Registration Pathway

CEL-SCI's Confirmatory Registration Study will enroll 212 newly diagnosed, previously untreated, locally advanced resectable head and neck cancer patients with low PD-L1 tumor expression and no lymph node involvement—the patient population that demonstrated the greatest benefit in the Company's completed Phase 3 study.

In that study, patients treated with Multikine before surgery and standard of care therapy achieved a 73% five-year overall survival rate compared to 45% for patients receiving standard of care alone. The confirmatory study is designed to show, among other things, significant improvement in overall survival and support potential registration of Multikine in the United States.

Saudi Market Entry Pathway

CEL-SCI has a strategic partnership with Amarox to support regulatory approval, commercialization and distribution of Multikine in Saudi Arabia. Under the agreement, Amarox is leading local regulatory activities and will be the exclusive distributor of Multikine in the Kingdom upon approval.

The partnership provides a 50%/50% revenue share for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation. Amarox is ranked #1 for Saudi-FDA (SFDA) applications for critical and unavailable medicine for 3 consecutive years. CEL-SCI retains ownership of all Multikine intellectual property, manufacturing know-how and global rights. The agreement also includes the option for Amarox to distribute Multikine throughout the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.

CEL-SCI and Amarox will conduct a formal signing ceremony during the BIO International Convention in San Diego on June 22, 2026 to highlight their collaboration and commitment to advancing Multikine in the region.

Addressing a Significant Unmet Need

Head and neck cancer is the 6th most common cancer, with approximately 900,000 newly diagnosed cases per year globally. The newly diagnosed stage 3 and 4 patients with this cancer represent a severe unmet need. The target population of the U.S. Confirmatory Registration Study represents approximately 100,000 newly diagnosed head and neck cancer patients annually. Based on CEL-SCI’s completed Phase 3 study of 928 patients, approximately 70% of head and neck cancer patients are estimated to have low or zero PD-L1 tumor expression, a population for whom currently available checkpoint inhibitors may offer only limited benefit with no definitive overall survival benefit.

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

New homes near Lake Hickory will offer one- and two-story floor plans from the $300s

, /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS)—a top national homebuilder, industry leader in online home sales, and featured on America's Most Trustworthy Companies by Newsweek—announced it will host a Grand Opening celebration for Cedar Hollow, the Company's new Hickory, NC community offering new homes with wooded homesites and versatile floor plans from the $300s.

Harlow Plan Exterior Rendering | New Homes in Hickory, NC | Cedar Hollow by Century Communities The Grand Opening weekend for Cedar Hollow will take place from 6/19 to 6/21, with the main event on Saturday, 6/20 at 11 a.m. The Opening will feature tours of the Harlow plan model and quick move-in homes, complimentary refreshments, and a giveaway. Following the Grand Opening weekend, a ribbon-cutting will be held on 6/30 at 11:30 a.m. with the Catawba County Chamber of Commerce.

Learn more, join the Interest List, and RVSP at www.CenturyCommunities.com/CedarHollowGO

"The Grand Opening event is the ideal time for buyers to make their move. With introductory pricing, first-in-line incentives, and competitive rates, homebuyers have a unique opportunity to make this community their own," said Division President Chris Suttles. "Offering a blend of small-town charm and big-city accessibility to the metro's key destinations, it's a place intentionally designed for the way life grows."

Floor plans at Cedar Hollow range up to 2,507 square feet and 5 bedrooms, featuring modern layouts, open kitchens, and premium features. 9' main-floor ceilings, LG® stainless-steel kitchen appliances, quartz countertops, and smart home package Century Home Connect® add beauty and quality to every residence. Select plans offer lofts, private studies, and main-floor primary suites, with options for electric fireplaces, covered patios, and additional bedrooms.

Positioned just off I-40, Cedar Hollow offers easy access to Asheville, Winston-Salem, and Charlotte. Downtown Hickory, Lake Hickory, Hickory Motor Speedway, and Hickory Crawdads baseball at L. P. Frans Stadium are all within 5.5 miles of the community, with Kool Park Pool nearby for summer recreation.

CEDAR HOLLOW | HICKORY, NC
Now selling from the low $300s

One- and two-story floor plans 1,327 to 2,507 square feet, 3 to 5 bedrooms, and 2 to 4.5 bathrooms Select plans offer lofts, patios, and main-floor primary suites Open kitchens, 9' main-floor ceilings, LG® stainless-steel kitchen appliances, and more Elevated finishes and Century Home Connect® smart home package Within 5.5 miles of downtown Hickory, Lake Hickory, Hickory Motor Speedway, and Hickory Crawdads baseball at L. P. Frans Stadium Two miles or less from elementary, middle, and high schools Easy access to Asheville, Winston-Salem, and Charlotte Location:
2955 31st Street NE
Hickory, NC 28601
704.216.1663

THE FREEDOM OF ONLINE HOMEBUYING

Century Communities is proud to feature its industry-first online homebuying experience on available homes in North Carolina, allowing homebuyers to easily find their best fit and purchase when they're ready—all while continuing to work with their local real estate agent of choice. Homebuyers can further streamline the homebuying process by financing online with Century Communities' affiliate lender, Inspire Home Loans®.

How it works:

Shop homes at CenturyCommunities.com Click "Buy Now" on any available home Fill out a quick Buy Online form Electronically submit an initial earnest money deposit Electronically sign a purchase contract via DocuSign® Learn more about the Buy Online experience at www.CenturyCommunities.com/online-homebuying.

About Century Communities
Century Communities, Inc. (NYSE: CCS) is one of the nation's largest homebuilders and a recognized industry leader in online home sales. Newsweek has named the Company one of America's Most Trustworthy Companies for four consecutive years. Century Communities has also been designated as one of U.S. News & World Report's Best Companies to Work For (2025–2026). Through its Century Communities and Century Complete brands, Century's mission is to build attractive, high-quality homes at affordable prices to provide its valued customers with A HOME FOR EVERY DREAM®. Century is engaged in all aspects of homebuilding — including the acquisition, entitlement and development of land, along with the construction, innovative marketing and sale of quality homes designed to appeal to a wide range of homebuyers. The Company operates in 16 states and over 45 markets across the U.S., and also offers mortgage, title, insurance brokerage, and escrow services in select markets through its Inspire Home Loans, Parkway Title, IHL Home Insurance Agency, and IHL Escrow subsidiaries. To learn more about Century Communities, please visit www.centurycommunities.com.

SOURCE Century Communities, Inc.

On June 16, 2026, AMN Healthcare Services Inc AMN shares rose 3.2% today to a current price of $31.88. The stock has experienced a notable 52-week range, with a low of $14.87 and a high of $32.52, reflecting significant volatility and investor interest in the healthcare sector.

GF Value™ verdict: Current price of $31.88 is 4.2% overvalued compared to a GF Value™ of $30.60.GF Score™ stands at 70/100, indicating an above-average potential for long-term returns.Notable signal: There have been no insider transactions in the last 3 months, suggesting a lack of insider buying or selling activity. Is AMN Overvalued or Undervalued? The current price of AMN Healthcare Services Inc is $31.88, which positions the stock as 4.2% overvalued when compared to the GF Value™ of $30.60. This slight overvaluation indicates that there may be limited margin of safety for potential investors, as the stock is trading above its calculated intrinsic value. The GF Valuation label categorizes AMN as fairly valued, but the current trading price suggests that investors may be paying a premium for the stock without clear justification based on its intrinsic value.

Investors should be cautious, as this overvaluation could pose risks, particularly in a fluctuating market. If the stock were to experience a downturn or if earnings fail to meet expectations, it could lead to a decline in stock price, exacerbating the risks associated with an overvalued stock. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does AMN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 12.0x 12.5x AMN's current P/E ratio of 12.0x is slightly below its 5-year median P/E of 12.5x, indicating that the stock is trading at a lower valuation compared to its historical levels. This suggests a potential mispricing relative to its historical performance, but it also aligns with the GF Value™ verdict of being overvalued. Thus, the P/E analysis supports the notion that while the stock may be undervalued relative to its history, the current price still reflects a premium over its intrinsic value.

What Does AMN's GF Score™ Tell Us? Metric Rating GF Score™ 70 Financial Strength 6/10 Profitability 7/10 Growth 1/10 Valuation 9/10 Momentum 6/10 AMN's GF Score™ of 70/100 reflects a well-rounded profile, with strengths in profitability (7/10) and valuation (9/10), indicating that the company has maintained solid profitability metrics and is perceived as relatively attractively priced. However, the growth rank of 1/10 suggests significant challenges in expanding revenue or earnings, which could limit future upside potential. The financial strength score of 6/10 indicates moderate stability, while the momentum rank of 6/10 suggests a mixed performance trend. Overall, the scores highlight the importance of focusing on both current valuation and potential growth challenges for AMN.

What Are Insiders Doing with AMN Stock? In the last three months, there have been no insider transactions reported for AMN Healthcare Services Inc. This lack of insider buying or selling activity could suggest that insiders are either confident in the company's current valuation or are awaiting more favorable conditions before making any transactions. Generally, insider buying can be a positive signal about the company's future prospects, while a lack of activity might imply uncertainty or a wait-and-see approach.

What This Means for Investors Based on the GF Value™, AMN Healthcare Services Inc is currently overvalued with a price of $31.88 compared to a GF Value™ of $30.60. While the company's GF Score™ indicates a solid performance in profitability and valuation, the growth rank signals potential limitations in its ability to expand. Investors should consider these factors carefully when evaluating AMN’s stock.

For the complete analysis, visit the AMN Healthcare Services Inc AMN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is AMN's GF Score™?

AMN's GF Score™ is 70/100, indicating an above-average potential for long-term returns based on its financial metrics.

Is AMN overvalued or undervalued?

AMN is currently overvalued, with a GF Value™ of $30.60 compared to its current price of $31.88.

What is AMN's P/E ratio?

AMN's current P/E ratio is 12.0x, which is below its 5-year median P/E of 12.5x, suggesting the stock is trading at a lower valuation compared to its historical levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

LOUISVILLE, Ky. -- June 16, 2026, June 16, 2026 (GLOBE NEWSWIRE) --

Chronic pain is shaping how millions of Americans live, move, sleep, work, and recover. New findings from Confluent Health suggest the healthcare system may still be falling short in addressing it. 

Today, Confluent Health officially launched The Pain Perspective, a groundbreaking new report capturing insights from more than 1,300 patients, musculoskeletal (MSK) clinicians, and referring physicians across the United States. The report offers one of the most comprehensive looks to date at how people experience chronic musculoskeletal (MSK) pain, the barriers preventing access to effective care, and what patients say they actually want from treatment. 

And the message is clear: patients are looking for more than temporary relief. They want care that restores movement, improves quality of life, and treats the whole person. 

Among the report’s key findings: 

85% of patients surveyed report living with chronic pain lasting longer than one yearMore than 80% say pain limits their daily activities65% report mental health challenges related to their painNearly half avoided seeking care because of cost9 in 10 would recommend physical therapy  The findings also reveal growing demand for conservative, non-pharmacologic care approaches focused on movement, education, and long-term recovery rather than symptom management alone. 

“Pain is not just physical, and patients are telling us that loudly and clearly,” said Dr. Kristi Henderson, CEO of Confluent Health. “What we’re seeing in this report is a growing disconnect between what patients need and what traditional pain care pathways have historically delivered. There is an enormous opportunity to rethink how care is designed, delivered, and experienced.” 

Patients surveyed overwhelmingly emphasized the importance of whole-person care, with 87% saying it is important for providers to address both physical and mental health as part of recovery. The report also found strong alignment among clinicians and referring physicians around movement-based treatment models and PT-first care pathways. 

For Confluent Health, The Pain Perspective is more than a report release. It’s the foundation of a broader movement to reshape how chronic pain is understood, discussed, and treated across the healthcare industry. Throughout 2026, the report will serve as the cornerstone of Confluent Health’s ongoing campaign exploring the realities of chronic pain through educational resources, executive thought leadership, patient storytelling, and “Pain, Misunderstood,” the organization’s powerful documentary examining the lived experiences behind the data. 

“At Confluent Health, we believe movement is medicine,” said Henderson. “Patients deserve care that helps them regain confidence, function, and hope. Not just temporarily manage symptoms.” 

The full report is available now at confluenthealth.com/pain-perspective.  

### 

About Confluent Health
Confluent Health, a nationwide network of physical and occupational therapy companies, is at the forefront of advancing musculoskeletal solutions that make us all stronger. We deliver better patient outcomes, reduce costs of care, improve workplace wellness, provide best-in-class education services, help prevent injuries, and play a crucial role in shaping industry best practices. For more information, visit confluenthealth.com or find us on LinkedIn. 

Contact Info

Caitlin Greenwell
[email protected]
+1 270-668-7886

Duolingo, Inc. (DUOL - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned +12.2%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Technology Services industry, which Duolingo falls in, has gained 1.8%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Duolingo is expected to post earnings of $0.62 per share for the current quarter, representing a year-over-year change of -31.9%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

For the current fiscal year, the consensus earnings estimate of $2.84 points to a change of -66.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $3.13 indicates a change of +10.5% from what Duolingo is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Duolingo is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Duolingo, the consensus sales estimate of $296.19 million for the current quarter points to a year-over-year change of +17.4%. The $1.21 billion and $1.36 billion estimates for the current and next fiscal years indicate changes of +16.4% and +12.5%, respectively.

Last Reported Results and Surprise HistoryDuolingo reported revenues of $291.97 million in the last reported quarter, representing a year-over-year change of +26.5%. EPS of $0.89 for the same period compares with $0.72 a year ago.

Compared to the Zacks Consensus Estimate of $288.54 million, the reported revenues represent a surprise of +1.19%. The EPS surprise was +12.66%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Duolingo is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Duolingo. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Top Marijuana Stocks to Watch in June 2026 The cannabis industry continues to evolve across the United States. Several operators are expanding their retail footprints while improving profitability. At the same time, investors are watching for regulatory changes that could support future growth. As a result, leading multi-state operators remain popular among cannabis-focused investors.

Green Thumb Industries, Cresco Labs, and Verano Holdings stand out within the sector. Each company operates in multiple legal cannabis markets. Additionally, each business has built recognizable brands and strong distribution networks. Their scale gives them advantages over smaller competitors. Therefore, these companies deserve attention during June 2026.

[Read More] Here Are 3 Marijuana Stocks To Follow For Better Investing

3 Top-Ranked Cannabis Stocks With Expanding U.S. Operations Green Thumb Industries (OTC: GTBIF) Cresco Labs (OTC: CRLBF) Verano Holdings (OTC: VRNOF) Green Thumb Industries (OTC: GTBIF) Green Thumb Industries is one of the largest cannabis operators in the United States. The company operates under several consumer brands. These include RYTHM, Dogwalkers, and Incredibles. Furthermore, Green Thumb has established a significant presence in many regulated markets.

Its largest presence remains in Illinois, Pennsylvania, and Florida. The company also maintains operations in states including Nevada, Maryland, New Jersey, and Virginia. Green Thumb operates approximately 100 dispensaries across the United States. This broad footprint provides access to millions of potential customers.

The company focuses on both retail and wholesale cannabis sales. Additionally, management continues expanding cultivation and manufacturing capacity. This strategy helps improve product availability and brand visibility. Meanwhile, Green Thumb has maintained a reputation for operational discipline. Investors often view the company as one of the sector’s strongest operators.

The business benefits from a diversified revenue base. No single market dominates overall results. Therefore, Green Thumb can better navigate state-specific challenges. Furthermore, its premium brands continue attracting loyal consumers. As legal cannabis markets mature, Green Thumb remains positioned for long-term expansion.

Latest Financials Green Thumb recently reported revenue that remained relatively stable despite industry pricing pressure. The company continues generating substantial cash flow from operations. Additionally, management has focused on preserving margins through cost controls.

Adjusted EBITDA remained among the strongest within the cannabis sector. This demonstrates the company’s operational efficiency. Furthermore, Green Thumb maintained a healthier balance sheet than many competitors. Investors continue to value that financial flexibility.

Retail sales accounted for the majority of revenue in recent quarters. However, wholesale sales also supported overall performance. Meanwhile, management continued investing in strategic growth initiatives. These investments target long-term market opportunities.

The company also maintained positive operating cash flow. That achievement remains important within the cannabis industry. Many operators still struggle to produce consistent profits. Therefore, Green Thumb’s financial performance stands out.

Looking ahead, management remains focused on disciplined growth. The company continues evaluating new market opportunities. Additionally, executives are emphasizing shareholder value creation. Strong financial execution could support future expansion plans. Consequently, Green Thumb remains a leading cannabis stock to watch during June 2026.

[Read More] Looking for Cannabis Exposure? These 3 Stocks Stand Out

Cresco Labs (OTC: CRLBF) Cresco Labs has built one of the largest wholesale cannabis platforms in America. The company operates a portfolio of well-known brands. These include Cresco, High Supply, Good News, and Mindy’s. Additionally, Cresco maintains a significant presence in major cannabis markets.

Its largest presence is concentrated in Illinois, Pennsylvania, and Ohio. The company also operates across several additional regulated states. Cresco currently operates approximately 70 dispensaries nationwide. Furthermore, it supplies products to hundreds of third-party retail locations.

Wholesale distribution remains a major competitive advantage. Unlike many cannabis operators, Cresco emphasizes broad product reach. Therefore, its brands appear in many stores beyond its own locations. This strategy helps expand market share efficiently.

The company continues investing in cultivation and manufacturing assets. Additionally, management remains focused on building brand recognition. Strong distribution capabilities support these efforts. Meanwhile, Cresco benefits from exposure to several high-population states.

Latest Financials Cresco’s diversified business model provides multiple revenue streams. Retail operations generate direct consumer relationships. At the same time, wholesale sales create additional growth opportunities. As a result, the company remains an important player within the cannabis industry.

Cresco Labs recently reported revenue reflecting ongoing competitive market conditions. Despite industry challenges, the company continued executing operational improvements. Furthermore, management remained focused on profitability initiatives.

Adjusted EBITDA remained a key financial metric for investors. The company worked to improve efficiency throughout its operations. Additionally, expense management efforts supported overall financial performance. These actions helped strengthen margins.

Retail revenue remained an important contributor to total sales. However, wholesale distribution continued to differentiate Cresco from competitors. This unique positioning supports broader market penetration. Consequently, the company maintains strong brand visibility.

Management also emphasized cash preservation and balance sheet improvement. These priorities remain important across the cannabis sector. Investors continue to reward companies demonstrating financial discipline. Cresco has worked consistently toward those objectives.

Looking ahead, the company expects opportunities from the expansion of cannabis markets. Additionally, new product launches could support revenue growth. Management remains focused on operational excellence and profitability. Therefore, Cresco Labs remains a cannabis stock worth monitoring during June 2026.

[Read More] 3 U.S. Marijuana Stocks With Strong Retail Footprints3 U.S. Marijuana Stocks With Strong Retail Footprints

Verano Holdings (OTC: VRNOF) Verano Holdings is another major multi-state cannabis operator. The company markets products through several established brands. These include Verano, Encore, Savvy, and MÜV. Furthermore, Verano has developed a broad retail network across key states.

Its largest presence is found in Florida, Illinois, and New Jersey. The company also operates facilities throughout numerous regulated markets. Verano currently operates approximately 150 dispensaries nationwide. This extensive footprint supports significant consumer reach.

The company combines retail operations with cultivation and manufacturing activities. As a result, Verano controls much of its supply chain. This vertical integration supports product consistency and margin management. Additionally, it strengthens brand positioning.

Management continues focusing on strategic market expansion. Meanwhile, Verano benefits from exposure to several limited-license states. Those markets often provide favorable competitive conditions. Therefore, the company enjoys opportunities for sustained growth.

Verano’s retail strategy centers on customer experience and premium products. Furthermore, its diversified geographic presence reduces dependence on any single market. This balanced approach has helped support long-term business development.

Latest Financials Verano recently reported revenue reflecting continued demand for cannabis products. The company maintained a substantial presence across its operating markets. Additionally, management focused on improving operational performance.

Adjusted EBITDA remained an important measure of profitability. Verano continued to implement cost-control initiatives across its business. These efforts helped support overall financial results. Furthermore, management emphasized efficiency improvements.

The company’s retail network remained a major revenue driver. However, cultivation and manufacturing operations also contributed significantly. This diversified model supports business stability. Therefore, Verano remains competitive within the cannabis sector.

Management has also concentrated on cash flow generation and balance sheet management. Investors increasingly prioritize these metrics. Consequently, financial discipline remains a central focus for the company.

Looking ahead, Verano appears positioned to benefit from future industry growth. Regulatory developments could create additional opportunities. Furthermore, the company’s established footprint provides a strong foundation. As a result, Verano Holdings remains one of the top marijuana stocks to watch in June 2026.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

-

HILLSBORO, Ore.--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in physical AI, advanced connectivity, security, and more.

Who: Lattice Semiconductor What / When (GMT+2): June 30 – July 2: Lattice Presentations & Demo Showcase Speaker sessions: Day 1 – 3 Speaker Sessions: Lattice FPGA deep dive sessions spanning physical AI, advanced connectivity, security, and design tools Date

Time

Session

June 30

9:45 a.m.

FPGA Verification and Testing by Arrow

11:15 a.m.

Trusted Resilience Edge: Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act

12 p.m.

SIPHashIP for Embedded Security: Enabling RED Compliance and CRA Readiness in Smart AR/VR Systems

2:15 p.m.

Foundations of FPGA Security and Hardware Identity by Arrow

July 1

9 a.m.

Solving Your Power Puzzle: Lattice FPGAs’ Path to Uncompromised Low Power

9:45 a.m.

Unlock Next-Gen SDR Design for SWaP-C Using Lattice FPGAs

1:30 p.m.

Security and Physical AI: FPGA Architectures for Systems That Sense and Act

5:15 p.m.

Role of Low Power FPGAs in Physical AI – Sensor Fusion, Compute Offloading, and Synchronization

July 2

9 a.m.

Efficient 360° Threat Detection for Parked Vehicles - A Distributed, Event-Driven Approach

9:45 a.m.

Building State of the Art Computer Vision Models for the Far Edge

11 a.m.

MIPI CSI-2 to USB 3.2 Video Pipeline with CrossLinkU-NX by Arrow

1:30 p.m.

Beyond the "Sledgehammer": Implementing Physical AI at the Sensor to Offload Robotic SoCs

2:15 p.m.

Smarter Robotics with Lattice FPGAs: From Vision to Motion

Reset Strategies by Arrow

3:30 p.m.

Efficient Vision Pipelines on FPGAs: Design Patterns and Performance Tuning

4:15 p.m.

Crypto-Factories: Homomorphic Encryption Powers FPGA-Accelerated Confidential Computing for Industrial Edge AI

Developing with Propel by Arrow

Where: FPGA Conference Europe, NH München Ost Conference Center, Munich, Germany The FPGA Conference Europe is Europe's leading specialist conference for programmable logic devices as the building blocks of datacenters, telecommunications, and many other technology applications.

Supporting Resources

For more information about Lattice, please visit https://www.latticesemi.com For more information about and to register for the conference, visit https://www.fpga-conference.eu/ About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

More News From Lattice Semiconductor

Back to Newsroom